|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF595 |
Gene summary for ZNF595 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF595 | Gene ID | 152687 |
| Gene name | zinc finger protein 595 | |
| Gene Alias | ZNF595 | |
| Cytomap | 4p16.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A075B7G4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 152687 | ZNF595 | P42T-E | Human | Esophagus | ESCC | 2.59e-04 | 1.05e-01 | 0.1175 |
| 152687 | ZNF595 | P47T-E | Human | Esophagus | ESCC | 1.55e-06 | 1.50e-01 | 0.1067 |
| 152687 | ZNF595 | P52T-E | Human | Esophagus | ESCC | 1.10e-06 | 1.32e-01 | 0.1555 |
| 152687 | ZNF595 | P54T-E | Human | Esophagus | ESCC | 5.72e-05 | 1.16e-01 | 0.0975 |
| 152687 | ZNF595 | P57T-E | Human | Esophagus | ESCC | 9.12e-09 | 1.06e-01 | 0.0926 |
| 152687 | ZNF595 | P61T-E | Human | Esophagus | ESCC | 2.78e-09 | 1.46e-01 | 0.099 |
| 152687 | ZNF595 | P62T-E | Human | Esophagus | ESCC | 2.27e-12 | 1.48e-01 | 0.1302 |
| 152687 | ZNF595 | P65T-E | Human | Esophagus | ESCC | 8.48e-08 | 9.95e-02 | 0.0978 |
| 152687 | ZNF595 | P74T-E | Human | Esophagus | ESCC | 1.64e-04 | 2.36e-01 | 0.1479 |
| 152687 | ZNF595 | P75T-E | Human | Esophagus | ESCC | 7.62e-13 | 2.06e-01 | 0.1125 |
| 152687 | ZNF595 | P76T-E | Human | Esophagus | ESCC | 3.87e-08 | 1.19e-01 | 0.1207 |
| 152687 | ZNF595 | P79T-E | Human | Esophagus | ESCC | 3.41e-26 | 4.91e-01 | 0.1154 |
| 152687 | ZNF595 | P80T-E | Human | Esophagus | ESCC | 9.33e-15 | 3.78e-01 | 0.155 |
| 152687 | ZNF595 | P83T-E | Human | Esophagus | ESCC | 3.57e-18 | 5.60e-01 | 0.1738 |
| 152687 | ZNF595 | P89T-E | Human | Esophagus | ESCC | 3.15e-05 | 3.25e-01 | 0.1752 |
| 152687 | ZNF595 | P107T-E | Human | Esophagus | ESCC | 1.01e-27 | 5.95e-01 | 0.171 |
| 152687 | ZNF595 | P128T-E | Human | Esophagus | ESCC | 3.60e-13 | 3.01e-01 | 0.1241 |
| 152687 | ZNF595 | P130T-E | Human | Esophagus | ESCC | 1.63e-05 | 1.09e-01 | 0.1676 |
| 152687 | ZNF595 | HCC1_Meng | Human | Liver | HCC | 1.88e-11 | -1.15e-02 | 0.0246 |
| 152687 | ZNF595 | HCC2 | Human | Liver | HCC | 4.43e-04 | 2.53e+00 | 0.5341 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ZNF595 | M1MAC | Cervix | ADJ | VNN3,ERO1B,KCNJ15, etc. | 1.36e-01 |  |
| ZNF595 | PLA | Cervix | ADJ | VNN3,ERO1B,KCNJ15, etc. | 2.57e-02 | |
| ZNF595 | TFH | Cervix | N_HPV | VNN3,ERO1B,KCNJ15, etc. | 8.89e-03 |  |
| ZNF595 | MAIT | Cervix | N_HPV | VNN3,ERO1B,KCNJ15, etc. | 9.06e-03 | |
| ZNF595 | BMEM | Colorectum | CRC | SPATA20,ABCB1,UEVLD, etc. | 4.29e-02 |  |
| ZNF595 | ILC | Colorectum | Healthy | SPATA20,ABCB1,UEVLD, etc. | 5.14e-02 |  |
| ZNF595 | END | Colorectum | MSI-H | NR1D2,AGBL4,CELSR1, etc. | 5.82e-01 |  |
| ZNF595 | ECC | Skin | AK | ZNF141,KDM7A-DT,GPX2, etc. | 1.11e-01 |  |
| ZNF595 | PIL | Skin | cSCC | ZNF141,KDM7A-DT,GPX2, etc. | 2.03e-02 |  |
| ZNF595 | FIB | Skin | ADJ | TOE1,PJA1,CWC22, etc. | 2.45e-02 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF595 | SNV | Missense_Mutation | novel | c.1657N>A | p.Glu553Lys | p.E553K | protein_coding | tolerated(1) | benign(0.015) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ZNF595 | SNV | Missense_Mutation | c.127N>A | p.Leu43Met | p.L43M | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-C8-A1HO-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR | ||
| ZNF595 | SNV | Missense_Mutation | novel | c.1177G>C | p.Glu393Gln | p.E393Q | protein_coding | deleterious(0.03) | probably_damaging(0.996) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF595 | SNV | Missense_Mutation | c.121N>T | p.Val41Phe | p.V41F | protein_coding | deleterious(0.02) | possibly_damaging(0.801) | TCGA-E2-A15M-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| ZNF595 | SNV | Missense_Mutation | novel | c.1273A>G | p.Thr425Ala | p.T425A | protein_coding | deleterious(0) | benign(0.023) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| ZNF595 | SNV | Missense_Mutation | novel | c.1856N>G | p.Ser619Cys | p.S619C | protein_coding | deleterious(0) | benign(0.327) | TCGA-EK-A3GJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZNF595 | SNV | Missense_Mutation | c.95N>C | p.Val32Ala | p.V32A | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
| ZNF595 | SNV | Missense_Mutation | novel | c.1024T>C | p.Cys342Arg | p.C342R | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF595 | SNV | Missense_Mutation | novel | c.60N>G | p.Cys20Trp | p.C20W | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-AA-3972-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | PD | |
| ZNF595 | SNV | Missense_Mutation | novel | c.1331N>T | p.Arg444Ile | p.R444I | protein_coding | tolerated(0.37) | possibly_damaging(0.776) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |